Clinical Trial Update: Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

View source ↗

Summary

This clinical trial update describes the ISMIO-001 study evaluating the combination of atezolizumab and bevacizumab with locoregional therapies for unresectable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Zhongda Hospital | Conditions: Unresectable Hepatocellular Carcinoma | Status: ACTIVE_NOT_RECRUITING